Tata 1mg turns Ebitda positive across all core businesses in FY26

Tata 1mg, India’s largest integrated digital healthcare platform, said it turned Ebitda positive across all its established business verticals in FY26, emerging as one of the few e-health companies in the country to achieve profitability at scale. 

The company said the performance marks the culmination of a decade-long effort to build an integrated healthcare platform spanning multiple verticals simultaneously. 

“This year has been a real inflection point. All our core businesses turned Ebitda positive in December and sustained that momentum through Q4,” said Prashant Tandon, Co-founder and CEO, Tata 1mg. He added that the profitability milestone reflects the company’s integrated healthcare model beginning to scale efficiently, improving both customer experience and unit economics. 

Tata 1mg said its e-pharmacy business, currently ranked number one in India, achieved breakeven during FY26 while continuing to expand operations. The company has rolled out express pharmacy delivery services within 30-60 minutes across 10 cities. 

Its diagnostics business also entered the ₹500-1,000 crore revenue scale among pathology players in India, registering over 40% year-on-year growth during FY26 while maintaining double-digit Ebitda margins. 

The company currently operates 19 NABL-accredited laboratories serving customers across 70 cities while its National Reference Lab holds CAP accreditation. 

Tata 1mg’s specialty pharma business, where it has a strong presence in patient support programmes, adult vaccination, cancer care, and obesity management, recorded 65% growth during the year. 

Its direct-to-consumer health products business crossed ₹200 crore in annual recurring revenue (ARR) and has remained profitable since inception, the company said. 

On the offline retail front, Tata 1mg operates more than 280 brick-and-mortar stores across nine clusters and plans to expand the network to over 500 stores in the next 12 months as part of its omnichannel growth strategy. 

“We operate in a very large market, where despite being a top player, we are not even 1% of the total market still,” Tandon said, adding that the company sees significant growth opportunities ahead. 

The company said it continues to invest heavily in technology and artificial intelligence as part of its long-term growth strategy. 

Its Health Insights Hub and Family Hub platforms are aimed at enabling more personalised and preventive healthcare experiences, while its AI-powered insights platform, Pulse, is now being used by more than 75 pharmaceutical companies. 

According to Tata 1mg, its next phase of growth over the next 12-24 months will focus on a cluster-driven expansion strategy integrating pharmacy, diagnostics and specialty care services across key geographies. 

The company identified faster pharmacy deliveries, diagnostics expansion into radiology and specialised testing, institutional partnerships and AI-led personalisation as key growth drivers for FY27 and beyond. “We see healthcare evolving towards being more personalised, predictive, and preventive — with trust at its core,” Tandon added.